SCHEMBL25250446

SCHEMBL25250446

Cn1cc(-c2cccc(NC(=O)c3cc4c(nc3OC3CC(O)C3)OC(C)(C)C4)n2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 20/20 1.00
RIPK2 O43353 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2C9 P11712 1/20 1.00
BRAF P15056 1/20 1.00
CYP2C19 P33261 1/20 1.00
FLT3 P36888 1/20 1.00
CLK1 P49759 1/20 1.00
IRAK1 P51617 1/20 1.00
RIPK1 Q13546 1/20 1.00
DYRK1A Q13627 1/20 1.00
STK38 Q15208 1/20 1.00
HIPK1 Q86Z02 1/20 1.00
STK17A Q9UEE5 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30428189 1.00 IRAK4 (1.00) IRAK4RIPK2CYP1A2CYP3A4CYP2C9
SCHEMBL25298174 1.00 IRAK4 (1.00) IRAK4RIPK2CYP1A2CYP3A4CYP2C9
SCHEMBL25297658 1.00 IRAK4 (1.00) IRAK4RIPK2CYP1A2CYP3A4CYP2C9
SCHEMBL30427723 1.00 IRAK4 (1.00) IRAK4RIPK2CYP1A2CYP3A4CYP2C9
SCHEMBL25245097 0.93 IRAK4 (1.00) IRAK4RIPK2CYP1A2CYP3A4CYP2C9
SCHEMBL25297787 0.91 IRAK4 (1.00) IRAK4RIPK2CYP1A2CYP3A4CYP2C9
SCHEMBL30428343 0.91 IRAK4 (1.00) IRAK4RIPK2CYP1A2CYP3A4CYP2C9
SCHEMBL25298434 0.91 IRAK4 (1.00) IRAK4RIPK2CYP1A2CYP3A4CYP2C9
SCHEMBL25298740 0.91 IRAK4 (1.00) IRAK4RIPK2CYP1A2CYP3A4CYP2C9
SCHEMBL25793298 0.91 IRAK4 (1.00) IRAK4RIPK2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074919-A1 Heteroaryl compounds as inhibitors of irak4, compositions and applications thereof ACCRO BIOSCIENCE HK LTD (HK) 2025-03-06 US disclosed
WO-2023130054-A2 HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF ACCRO BIOSCIENCE (HK) LIMITED (CN) 2023-07-06 WO disclosed
WO-2023130054-A2 HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF ACCRO BIOSCIENCE (HK) LIMITED (CN) 2023-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074919-A1 Heteroaryl compounds as inhibitors of irak4, compositions and applications thereof IRAK4, IRAK1, IRAK2 IRAK4 1/4885RIPK2 30/4885CYP1A2 4404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.